The political winds seem to be blowing in favor of a Congressional vote on the U.S.-Mexico-Canada Free Trade Agreement (USMCA) yet this fall. But before they vote, some Members of Congress want to talk over a few issues with the Trump administration’s negotiators. One is intellectual property protections for the U.S. biopharmaceutical industry. As important as it is, the issue of data protection for biologic drugs is not well understood.
Economists can’t tell you how tariffs impact your own business, your job or your shopping cart. Nonetheless, as tariffs are set to go higher, we look at how economists are dialing the tariffs into their forecasts about growth for the U.S. and global economy.
Just hours after signing the United States-Mexico-Canada Agreement in December last year, President Trump said, “Congress will have a choice of the USMCA or pre-NAFTA, which worked very well.” On the tariff side at least, while a no-USMCA scenario is bad, no NAFTA is most definitely worse.